Benzinga's Top #PreMarket Losers By: Benzinga via Benzinga March 18, 2015 at 08:14 AM EDT Nektar Therapeutics (NASDAQ: NKTR) shares fell 16.50% to $11.80 in pre-market trading after the company said its breast cancer ... Read More >> Related Stocks: Adobe Systems Bioplus Acquisition Corp Cl A Nektar Therapeutics RSP Permian, Inc. Common Stock